Kato N, Halprin K M, Taylor J R, Ohkawara A
Department of Dermatology, Hokkaido University School of Medicine, Sapporo, Japan.
Arch Dermatol Res. 1988;280(2):89-92. doi: 10.1007/BF00417710.
It has been known that beta-adrenergic adenylate cyclase response is decreased in psoriatic-involved epidermis. Since the immunosuppressive agent, cyclosporin A, is reported to be effective on psoriasis clinically, the effect of cyclosporin A on beta-adrenergic adenylate cyclase response in pig skin was examined in vitro. Therapeutic serum levels of cyclosporin A (100-400 ng/ml) augmented the beta-adrenergic adenylate cyclase response of the epidermis. Highest levels of cyclosporin A (2-20 micrograms/ml) did not have any effect on its response. Both low Km and high Km cyclic AMP phosphodiesterases were not affected by cyclosporin A. Therefore, it is suggested that the clinical efficacy of cyclosporin A on psoriasis can be explained partially by its direct effect on the keratinocyte itself.
已知银屑病累及的表皮中β-肾上腺素能腺苷酸环化酶反应降低。由于免疫抑制剂环孢素A在临床上据报道对银屑病有效，因此在体外研究了环孢素A对猪皮肤中β-肾上腺素能腺苷酸环化酶反应的影响。治疗血清水平的环孢素A（100 - 400 ng/ml）增强了表皮的β-肾上腺素能腺苷酸环化酶反应。最高水平的环孢素A（2 - 20μg/ml）对其反应没有任何影响。低Km和高Km的环磷酸腺苷磷酸二酯酶均不受环孢素A的影响。因此，提示环孢素A对银屑病的临床疗效可部分由其对角质形成细胞本身的直接作用来解释。
Zotero 插件